185 related articles for article (PubMed ID: 28360530)
1. Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy.
Chen W; Fan L; Wang Y; Deng X
J Pain Res; 2017; 10():621-624. PubMed ID: 28360530
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
3. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Gao Y; Jin H
Dermatol Ther; 2021 Sep; 34(5):e15051. PubMed ID: 34197012
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.
Drabik A; Hillgruber C; Goerge T
JMIR Res Protoc; 2014 Dec; 3(4):e73. PubMed ID: 25500152
[TBL] [Abstract][Full Text] [Related]
6. Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Zhao C; Yu M; Cheng X; Li S; Feng S
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38287670
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Leisenring NH; Rogers JL; Telloni S; Mansoori P; Al-Rohil RN; Marano AL
J Drugs Dermatol; 2020 May; 19(5):544-546. PubMed ID: 32484618
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
[TBL] [Abstract][Full Text] [Related]
11. A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.
Song CH; Shin DS; Jang JW; Kim TL; Kim YG; Kim JS; Seo HM
Ann Dermatol; 2020 Dec; 32(6):508-511. PubMed ID: 33911794
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
[No Abstract] [Full Text] [Related]
13. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
Kerk N; Goerge T
J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
[TBL] [Abstract][Full Text] [Related]
14. Livedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review.
Gao Y; Jin H
Int Wound J; 2023 May; 20(5):1498-1505. PubMed ID: 36333819
[TBL] [Abstract][Full Text] [Related]
15. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.
Yoshioka K; Tateishi C; Kato H; Chen KR
Clin Case Rep; 2018 Nov; 6(11):2045-2047. PubMed ID: 30455888
[TBL] [Abstract][Full Text] [Related]
17. Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.
Palanisamy N; Chinnappan J; Bachuwa G
Eur J Case Rep Intern Med; 2023; 10(1):003727. PubMed ID: 36819654
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of livedoid vasculopathy with rivaroxaban.
Evans JM; Jensen JD; Sami N
JAAD Case Rep; 2015 Nov; 1(6):340-1. PubMed ID: 27051773
[No Abstract] [Full Text] [Related]
19. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
20. Livedoid vasculopathy - a thrombotic disease.
Kerk N; Goerge T
Vasa; 2013 Sep; 42(5):317-22. PubMed ID: 23989066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
